170 related articles for article (PubMed ID: 22354705)
21. Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.
Canazza I; Ossato A; Trapella C; Fantinati A; De Luca MA; Margiani G; Vincenzi F; Rimondo C; Di Rosa F; Gregori A; Varani K; Borea PA; Serpelloni G; Marti M
Psychopharmacology (Berl); 2016 Oct; 233(21-22):3685-3709. PubMed ID: 27527584
[TBL] [Abstract][Full Text] [Related]
22. The cannabinoid agonist WIN 55,212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells.
Nilsson O; Fowler CJ; Jacobsson SO
Eur J Pharmacol; 2006 Oct; 547(1-3):165-73. PubMed ID: 16928371
[TBL] [Abstract][Full Text] [Related]
23. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
Calik MW; Carley DW
Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
[TBL] [Abstract][Full Text] [Related]
24. Role of CB2 receptors and cGMP pathway on the cannabinoid-dependent antiepileptic effects in an in vivo model of partial epilepsy.
Rizzo V; Carletti F; Gambino G; Schiera G; Cannizzaro C; Ferraro G; Sardo P
Epilepsy Res; 2014 Dec; 108(10):1711-8. PubMed ID: 25458534
[TBL] [Abstract][Full Text] [Related]
25. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.
Liu C; Walker JM
J Neurophysiol; 2006 Dec; 96(6):2984-94. PubMed ID: 16943316
[TBL] [Abstract][Full Text] [Related]
26. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
de Lago E; Moreno-Martet M; Cabranes A; Ramos JA; Fernández-Ruiz J
Neuropharmacology; 2012 Jun; 62(7):2299-308. PubMed ID: 22342378
[TBL] [Abstract][Full Text] [Related]
27. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Johanek LM; Simone DA
Pain; 2004 Jun; 109(3):432-442. PubMed ID: 15157704
[TBL] [Abstract][Full Text] [Related]
28. The cannabinoid receptor agonist WIN 55,212-2 inhibits antigen-induced plasma extravasation in guinea pig airways.
Fukuda H; Abe T; Yoshihara S
Int Arch Allergy Immunol; 2010; 152(3):295-300. PubMed ID: 20150748
[TBL] [Abstract][Full Text] [Related]
29. The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.
Uhelski ML; Cain DM; Harding-Rose C; Simone DA
Neuroscience; 2013 Sep; 247():84-94. PubMed ID: 23673278
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoid receptor agonists modulate calcium channels in rat retinal Müller cells.
Yang W; Li Q; Wang SY; Gao F; Qian WJ; Li F; Ji M; Sun XH; Miao Y; Wang Z
Neuroscience; 2016 Jan; 313():213-24. PubMed ID: 26621126
[TBL] [Abstract][Full Text] [Related]
31. CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations.
Citraro R; Russo E; Ngomba RT; Nicoletti F; Scicchitano F; Whalley BJ; Calignano A; De Sarro G
Epilepsy Res; 2013 Sep; 106(1-2):74-82. PubMed ID: 23860329
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2.
Scholl A; Ivanov I; Hinz B
Oncotarget; 2016 Sep; 7(38):61438-61457. PubMed ID: 27556861
[TBL] [Abstract][Full Text] [Related]
33. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.
Suplita RL; Eisenstein SA; Neely MH; Moise AM; Hohmann AG
Neuropharmacology; 2008 Jan; 54(1):161-71. PubMed ID: 17714742
[TBL] [Abstract][Full Text] [Related]
34. Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation.
De Filippis D; Russo A; De Stefano D; Maiuri MC; Esposito G; Cinelli MP; Pietropaolo C; Carnuccio R; Russo G; Iuvone T
J Mol Med (Berl); 2007 Jun; 85(6):635-45. PubMed ID: 17447045
[TBL] [Abstract][Full Text] [Related]
35. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic-pharmacodynamic influence of N-palmitoylethanolamine, arachidonyl-2'-chloroethylamide and WIN 55,212-2 on the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice.
Citraro R; Russo E; Leo A; Russo R; Avagliano C; Navarra M; Calignano A; De Sarro G
Eur J Pharmacol; 2016 Nov; 791():523-534. PubMed ID: 27663280
[TBL] [Abstract][Full Text] [Related]
37. Endocannabinoid mechanism for orofacial antinociception induced by electroacupuncture in acupoint St36 in rats.
Almeida RT; Romero TR; Romero MG; de Souza GG; Perez AC; Duarte ID
Pharmacol Rep; 2016 Dec; 68(6):1095-1101. PubMed ID: 27573715
[TBL] [Abstract][Full Text] [Related]
38. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
39. Influence of intracerebroventricular or intraperitoneal administration of cannabinoid receptor agonist (WIN 55,212-2) and inverse agonist (AM 251) on the regulation of food intake and hypothalamic serotonin levels.
Merroun I; Errami M; Hoddah H; Urbano G; Porres JM; Aranda P; Llopis J; López-Jurado M
Br J Nutr; 2009 May; 101(10):1569-78. PubMed ID: 19245736
[TBL] [Abstract][Full Text] [Related]
40. Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury.
Brownjohn PW; Ashton JC
Neuroscience; 2012 Feb; 203():180-93. PubMed ID: 22210507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
